This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hagiwara, K. Articles by Harris, C. C. Search for Related Content PubMed PubMed Citation Articles by Hagiwara, K. Articles by Harris, C. C.

Mutational Analysis of the p63/p73L/p51/p40/CUSP/KET Gene in Human Cancer Cell Lines Using Intronic Primers

Laboratory of Human Carcinogenesis, National Cancer Institute, NIH, Bethesda, Maryland 20892

After the identification of p73, a second homologue of the human p53 tumor suppressor gene has been reported and named p63/p73L/p51/p40/CUSP/KET. We have investigated the hypotheses that: (a) p63 is mutated in diverse types of human cancers; and (b) p63 functions in the same pathway as p53 and p73 in the process of carcinogenesis; therefore, mutations in these three genes would be mutually exclusive. We have analyzed the genomic structure of the p63 gene and have performed mutational analyses on 54 human cell lines using intronic primers flanking each exon. We have confirmed that the human p63 open reading frame encodes the same length of protein as murine p63 that was initially reported to be 39 amino acids longer than human p63. By mutational analysis, we have shown that DLD1 and SKOV3 cells have either heterozygous mutations or polymorphisms in the putative DNA binding domain of p63. In these cell lines, p63 is biallelically expressed. We conclude that mutations in the p63 gene are rare in human cell lines. The fact that DLD1 is abnormal for both p63 and p53 genes suggests that they may not be involved in the same tumor suppressor pathway.

This article has been cited by other articles:

				R. D. Kirschner, K. Sanger, G. A. Muller, and K. Engeland Transcriptional activation of the tumor suppressor and differentiation gene S100A2 by a novel p63-binding site Nucleic Acids Res., May 1, 2008; 36(9): 2969 - 2980. [Abstract] [Full Text] [PDF]

				K.E. King, R.M. Ponnamperuma, M.J. Gerdes, T. Tokino, T. Yamashita, C.C. Baker, and W.C. Weinberg Unique domain functions of p63 isotypes that differentially regulate distinct aspects of epidermal homeostasis Carcinogenesis, January 1, 2006; 27(1): 53 - 63. [Abstract] [Full Text] [PDF]

				S.-i. Kurata, T. Okuyama, M. Osada, T. Watanabe, Y. Tomimori, S. Sato, A. Iwai, T. Tsuji, Y. Ikawa, and I. Katoh p51/p63 Controls Subunit {alpha}3 of the Major Epidermis Integrin Anchoring the Stem Cells to the Niche J. Biol. Chem., November 26, 2004; 279(48): 50069 - 50077. [Abstract] [Full Text] [PDF]

				S. Kim, J. Han, J. Kim, and C. Park Maspin Expression Is Transactivated by p63 and Is Critical for the Modulation of Lung Cancer Progression Cancer Res., October 1, 2004; 64(19): 6900 - 6905. [Abstract] [Full Text] [PDF]

				M. D. Westfall and J. A. Pietenpol p63: molecular complexity in development and cancer Carcinogenesis, June 1, 2004; 25(6): 857 - 864. [Abstract] [Full Text] [PDF]

				S. P. Hussain, P. Amstad, P. He, A. Robles, S. Lupold, I. Kaneko, M. Ichimiya, S. Sengupta, L. Mechanic, S. Okamura, et al. p53-Induced Up-Regulation of MnSOD and GPx but not Catalase Increases Oxidative Stress and Apoptosis Cancer Res., April 1, 2004; 64(7): 2350 - 2356. [Abstract] [Full Text] [PDF]

				F. Koga, S. Kawakami, Y. Fujii, K. Saito, Y. Ohtsuka, A. Iwai, N. Ando, T. Takizawa, Y. Kageyama, and K. Kihara Impaired p63 Expression Associates with Poor Prognosis and Uroplakin III Expression in Invasive Urothelial Carcinoma of the Bladder Clin. Cancer Res., November 15, 2003; 9(15): 5501 - 5507. [Abstract] [Full Text] [PDF]

				P. P. Massion, P. M. Taflan, S. M. Jamshedur Rahman, P. Yildiz, Y. Shyr, M. E. Edgerton, M. D. Westfall, J. R. Roberts, J. A. Pietenpol, D. P. Carbone, et al. Significance of p63 Amplification and Overexpression in Lung Cancer Development and Prognosis Cancer Res., November 1, 2003; 63(21): 7113 - 7121. [Abstract] [Full Text] [PDF]

				C. Langner, M. Ratschek, O. Tsybrovskyy, L. Schips, and R. Zigeuner P63 Immunoreactivity Distinguishes Upper Urinary Tract Transitional-cell Carcinoma and Renal-cell Carcinoma Even in Poorly Differentiated Tumors J. Histochem. Cytochem., August 1, 2003; 51(8): 1097 - 1099. [Abstract] [Full Text] [PDF]

				K. Hagiwara, T. Kikuchi, Y. Endo, Huqun, K. Usui, M. Takahashi, N. Shibata, T. Kusakabe, H. Xin, S. Hoshi, et al. Mouse SWAM1 and SWAM2 Are Antibacterial Proteins Composed of a Single Whey Acidic Protein Motif J. Immunol., February 15, 2003; 170(4): 1973 - 1979. [Abstract] [Full Text] [PDF]

				L L Barrow, H van Bokhoven, S Daack-Hirsch, T Andersen, S E C van Beersum, R Gorlin, and J C Murray Analysis of the p63 gene in classical EEC syndrome, related syndromes, and non-syndromic orofacial clefts J. Med. Genet., August 1, 2002; 39(8): 559 - 566. [Abstract] [Full Text] [PDF]

				P. H. G. Duijf, K. R. J. Vanmolkot, P. Propping, W. Friedl, E. Krieger, F. McKeon, V. Dotsch, H. G. Brunner, and H. van Bokhoven Gain-of-function mutation in ADULT syndrome reveals the presence of a second transactivation domain in p63 Hum. Mol. Genet., April 1, 2002; 11(7): 799 - 804. [Abstract] [Full Text] [PDF]

				H. Nishi, M. Senoo, K. H. Nishi, B. Murphy, T. Rikiyama, Y. Matsumura, S. Habu, and A. C. Johnson p53 Homologue p63 Represses Epidermal Growth Factor Receptor Expression J. Biol. Chem., November 2, 2001; 276(45): 41717 - 41724. [Abstract] [Full Text] [PDF]

				Y. Suliman, O. G. Opitz, A. Avadhani, T. C. Burns, W. El-Deiry, D. T. Wong, and A. K. Rustgi p63 Expression Is Associated with p53 Loss in Oral-Esophageal Epithelia of p53-deficient Mice Cancer Res., September 1, 2001; 61(17): 6467 - 6473. [Abstract] [Full Text] [PDF]

				G. BOUGEARD, J.-M. LIMACHER, C. MARTIN, F. CHARBONNIER, A. KILLIAN, O. DELATTRE, M. LONGY, P. JONVEAUX, J.-P. FRICKER, D. STOPPA-LYONNET, et al. Detection of 11 germline inactivating TP53 mutations and absence of TP63 and HCHK2 mutations in 17 French families with Li-Fraumeni or Li-Fraumeni-like syndrome J. Med. Genet., April 1, 2001; 38(4): 253 - 257. [Full Text]

				E. A. Ratovitski, M. Patturajan, K. Hibi, B. Trink, K. Yamaguchi, and D. Sidransky p53 associates with and targets Delta Np63 into a protein degradation pathway PNAS, February 13, 2001; 98(4): 1817 - 1822. [Abstract] [Full Text] [PDF]

				J. A. McGrath, P. H.G. Duijf, V. Doetsch, A. D. Irvine, R. d. Waal, K. R.J. Vanmolkot, V. Wessagowit, A. Kelly, D. J. Atherton, W. A. D. Griffiths, et al. Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63 Hum. Mol. Genet., February 1, 2001; 10(3): 221 - 229. [Abstract] [Full Text] [PDF]

				B.-J. Park, S.-J. Lee, J. I. Kim, S.-J. Lee, C.-H. Lee, S.-G. Chang, J.-H. Park, and S.-G. Chi Frequent Alteration of p63 Expression in Human Primary Bladder Carcinomas Cancer Res., July 1, 2000; 60(13): 3370 - 3374. [Abstract] [Full Text]

				K. Hibi, B. Trink, M. Patturajan, W. H. Westra, O. L. Caballero, D. E. Hill, E. A. Ratovitski, J. Jen, and D. Sidransky AIS is an oncogene amplified in squamous cell carcinoma PNAS, May 9, 2000; 97(10): 5462 - 5467. [Abstract] [Full Text] [PDF]

				S. Kato, A. Shimada, M. Osada, S. Ikawa, M. Obinata, A. Nakagawara, R. Kanamaru, and C. Ishioka Effects of p51/p63 Missense Mutations on Transcriptional Activities of p53 Downstream Gene Promoters Cancer Res., December 1, 1999; 59(23): 5908 - 5911. [Abstract] [Full Text] [PDF]